The global pyrimethamine market is expected to grow at a significant CAGR during the forecast period (2021-2027). Pyrimethamine is a protozoan infection treatment drug. It's frequently used as an antimalarial medication (for both treatment and prevention of malaria) as well as to treat Toxoplasma gondii infections, especially when coupled with the sulfonamide antibiotic sulfadiazine in HIV-positive patients. Owing to its resistance to several plasmodium species, pyrimethamine is usually combined with sulfonamide and folinic acid. Pyrimethamine has also been shown to suppress the expression of the superoxide dismutase 1 gene, which is linked to amyotrophic lateral sclerosis.

Pyrimethamine is a folic acid antagonist that is used as an antimalarial or in combination with a sulphonamide to treat toxoplasmosis. Pyrimethamine prevents the production of purines and pyrimidines, which are required for DNA synthesis and cell proliferation, by inhibiting plasmodia dihydrofolate reductase. Nuclear division failure occurs during schizont development in erythrocytes and the liver as a result of this process. It's often utilized as a supplement in the treatment of uncomplicated P. falciparum malaria that's resistant to chloroquine.

According to the World Health Organization's (WHO) "World Malaria Report 2018," there were an estimated 219 million cases and over 435,000 mortalities from malaria in 2017, with Plasmodium falciparum accounting for the majority of cases. As a result, the increased prevalence of malaria is driving this market growth. Pyrimethamine is on the WHO’s list of essential medicines as one of the most critical drugs. The potential of pyrimethamine to cure protozoan and toxoplasma infections, as well as the growing number of HIV-positive patients globally and immunosuppressed individuals at risk of infections, are driving the market growth during the forecast period.

Pyrimethamine Tablets USP, 25 mg, a therapeutic equivalent and first-wave generic version of Daraprim (pyrimethamine) Tablets, was launched by Dr. Reddys Laboratories and was authorized by the US Food and Drug Administration (USFDA) in March 2020. The USFDA has authorized this generic version of Daraprim (pyrimethamine) Tablets as the sole AB-rated generic version of Daraprim (pyrimethamine) Tablets.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered- 

o By Type – Tablets, Capsules, Injectables

o By Drug – Daraprim and Fansidar

o By End-User vertical – Hospitals and Clinics, Laboratories, and Others

• Competitive Landscape: Evaluate, Pfizer Inc., Pfizer Inc. GlaxoSmithKline plc., and others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Pyrimethamine Market Report 

By Type

• Tablets
• Capsules
• Injectables

By Drug

• Daraprim
• Fansidar

By End-User vertical

• Hospitals and Clinics
• Laboratories 
• Others

By Region